Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting

Dec 1 2010

New data on UCB's anti-epileptic drug (AED) Vimpat® (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking place at the San Antonio Convention Center in San Antonio, Texas from December 3 to 7, 2010.  Data will also be presented on Keppra XR and the investigative epilepsy therapy, brivaracetam.

Vimpat® tablets and injection were launched in the U.S. in May 2009 as an add-on therapy for the treatment of partial-onset seizures (POS) in people with epilepsy who are 17 years and older.  Vimpat® injection is a short-term replacement when oral administration is not feasible in these patients.  Vimpat® oral solution was launched in June 2010.  The availability of the oral tablets, oral solution, and intravenous (IV) injection allows for consistent treatment in a hospital setting.  The maximum recommended daily dose for Vimpat® in the U.S. is 400 mg/day.

Keppra XR® was approved in September 2008 as an add-on therapy for POS in patients who are 16 years of age and older with epilepsy.  UCB is investigating brivaracetam as an adjunctive treatment of POS in adults with epilepsy.  Brivaracetam is not currently approved by the U.S. Food and Drug Administration.

Following is a guide to UCB-sponsored posters for Vimpat®, Keppra XR® and brivaracetam to be presented at the AES annual meeting.  Additional UCB-sponsored data will be presented during a scientific exhibit on Sunday, December 5, 8 AM-11 AM EST.

To schedule an interview with an investigator, please contact Andrea Levin at 404.483.7329 or [email protected].  

UCB-Sponsored Posters

Vimpat® (lacosamide) C-V:

1. Improved Seizure Severity, Health-Related Quality of Life and Health Status Reported by Patients During Long-Term Treatment with Lacosamide

Abstract 1.262, Saturday, December 4, Noon - 2:00 pm, Hall A, Street Level

2. Long-Term Safety of Lacosamide as Adjunctive Therapy in Subjects With Uncontrolled POS: Results from a Phase III Open-Label Extension Trial

Abstract 1.265, Saturday, December 4, Noon - 2:00 pm, Hall A, Street Level

3. Long-term Efficacy of Lacosamide as Adjunctive Therapy in Subjects with Uncontrolled POS: Results from a Phase III Open-Label Extension Trial

Abstract 1.263, Saturday, December 4, Noon - 2:00 pm, Hall A, Street Level

4. Investigation of Lacosamide Binding to Collapsin Response Mediator Protein-2 (CRMP-2)

Abstract 1.247, Saturday, December 4, Noon - 2:00 pm, Hall A, Street Level

5. Safety of Lacosamide Monotherapy in Migraine Prophylaxis, Fibromyalgia, and Osteoarthritis: Placebo-controlled Evaluations

Abstract 1.284, Saturday, December 4, Noon - 2:00 pm, Hall A, Street Level

6. Lacosamide Does Not Alter Bone Densitometry Parameters in Juvenile Dogs

Abstract 2.191, Sunday, December 5, Noon - 2:00 pm, Hall A, Street Level

Keppra XR®:

7. Levetiracetam Extended-Release Conversion to Monotherapy for the Treatment of Patients with Partial-Onset Seizures: A Double-Blind, Randomized, Multicenter, Historical Control Study

Abstract 1.282, Saturday, December 4, Noon - 2:00 pm, Hall A, Street Level

8. Pharmacokinetics, Safety and Tolerability of Levetiracetam Extended-Release in Children and Adults with Epilepsy

Abstract 1.278, Saturday, December 4, Noon - 2:00 pm, Hall A, Street Level

9. UCB Antiepileptic Drug Pregnancy Registry

Abstract 1.257, Saturday, December 4, Noon - 2:00 pm, Hall A, Street Level

Brivaracetam:

10. The Impact of Standardization on the Magnitude of Treatment Effect When Analyzing Log-Transformed Seizure Outcome

Abstract 1.256, Saturday, December 4, Noon - 2:00 pm, Hall A, Street Level

11. Adjunctive Brivaracetam in Adults with Uncontrolled Generalized Seizures: Sub-Population Analysis of the Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Abstract 1.267, Saturday, December 4, Noon - 2:00 pm, Hall A, Street Level